DurgicalDurgical
EN
Open the app

Insulin aspart !

A rapid-acting insulin analogue for meals and pumps. One amino acid change lets it break apart and enter the blood quickly.

Updated 2026-11-01

  • Class: Insulins
  • Receptor: Insulin receptor
  • ATC code: A10AB05
  • WHO Model List of Essential Medicines

The figure shows human insulin bound to site 1 of an insulin receptor fragment. Aspart differs only at B28 and binds the same site.

Target in 3D: Insulin receptor. PDB structure 4OGA (RCSB PDB, public domain). View the structure at RCSB PDB

Mechanism of action

In insulin aspart the proline at B28 is replaced by aspartic acid. The added negative charge reduces self-association, so the hexamers dissociate rapidly into monomers after injection and are absorbed faster than regular insulin. Once in the blood it acts on the insulin receptor exactly like human insulin.

  1. Aspartate at B28 reduces self-association
  2. Monomers are absorbed rapidly from under the skin
  3. Activates the insulin receptor like human insulin
  4. Covers the glucose rise of a meal

Pharmacokinetics

Absorption
Subcutaneous, faster than regular insulin; intravenous use only under medical supervision.
Half-life
Apparent half-life after a subcutaneous injection of about 81 minutes in the label's study.
Onset and duration
Injected 5 to 10 minutes before a meal; the greatest glucose-lowering effect occurs between 1 and 3 hours after injection.

Indications

Adverse effects

Common

  • Hypoglycemia
  • Weight gain
  • Injection-site reactions and lipodystrophy
  • Low potassium

Contraindications

  • During an episode of hypoglycemia
  • Hypersensitivity to insulin aspart or an excipient

Key interactions

Beta-blockers, clonidine
Can blunt the warning signs of hypoglycemia.
Other glucose-lowering drugs
Raise the risk of hypoglycemia.
Corticosteroids, diuretics, atypical antipsychotics, niacin
Reduce the glucose-lowering effect.
Thiazolidinediones (pioglitazone)
Fluid retention and possible heart failure.

What is monitored

  • Blood glucose before and after meals
  • Glucose and potassium closely during intravenous use
  • HbA1c
  • Pump and injection sites

Administration and safety

  • Subcutaneous injection shortly before a meal, or continuous subcutaneous infusion by pump.
  • Intravenous use only under medical supervision, with close checks of glucose and potassium.
  • In a pump it is not diluted or mixed with other insulins.
  • Look-alike risk with premixed aspart products: the label is checked before every dose.

Nursing care

  • Before: blood glucose and confirmation that the meal is available.
  • After: watch for hypoglycemia in the first hours.
  • Review the dose with the team if the patient cannot eat.
  • Teach pump users to recognize pump failure and to have a backup injection plan.

Pregnancy and breastfeeding

Rapid analogues such as aspart are used in pregnancy; insulin needs change by trimester and glucose is checked often.

Test yourself

Think of the answer, then tap the question to see it.

Which single change makes insulin aspart rapid acting?

Proline B28 is replaced by aspartic acid, which reduces self-association so the insulin dissociates quickly into monomers.

When does aspart's glucose-lowering effect peak after a subcutaneous injection?

Between about 1 and 3 hours after the injection.

What extra monitoring is needed when aspart is given intravenously?

Close blood glucose and potassium monitoring, under medical supervision, to avoid hypoglycemia and hypokalemia.

Add to my cards (3)

← Back to the class: Insulins

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Insulin Aspart (rDNA Origin) Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2025); DailyMed - INSULIN ASPART injection, solution (DailyMed (U.S. National Library of Medicine), 2026); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 51 (McGraw Hill, 2023); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.